Irrespective of age, duration of disease, and other factors, people with rheumatoid arthritis have a consistently higher risk for venous thromboembolism than the general population.
In studies with an average follow-up of 16 weeks, there was no significant increase in MACE or VTE rates in people with dermatoses treated with JAK-STAT inhibitors.